Otologic Pharmaceutics
Oklahoma City
About Otologic Pharmaceutics
Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders. OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2014)
- Website: otologicpharmaceutics.com
- Phone: (405)319-8165
Industries & Categories
Biotechnology, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/otologic-pharmaceutics-2453066 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.